135 related articles for article (PubMed ID: 9084851)
1. Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells.
Buell JF; Reed E; Lee KB; Parker RJ; Venzon DJ; Amikura K; Arnold S; Fraker DL; Alexander HR
Ann Surg Oncol; 1997 Mar; 4(2):141-8. PubMed ID: 9084851
[TBL] [Abstract][Full Text] [Related]
2. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha.
Mizutani Y; Bonavida B
Cancer; 1993 Aug; 72(3):809-18. PubMed ID: 8334635
[TBL] [Abstract][Full Text] [Related]
3. The impact of hyperthermic chemotherapy on human gastric cancer cell lines: preliminary results.
Tang R; Zhu ZG; Qu Y; Li JF; Ji YB; Cai Q; Liu BY; Yan M; Yin HR; Lin YZ
Oncol Rep; 2006 Sep; 16(3):631-41. PubMed ID: 16865266
[TBL] [Abstract][Full Text] [Related]
4. Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum.
Uslu R; Bonavida B
Cancer; 1996 Feb; 77(4):725-32. PubMed ID: 8616765
[TBL] [Abstract][Full Text] [Related]
5. Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo.
Gharehbaghi K; Szekeres T; Yalowitz JA; Fritzer-Szekeres M; Pommier YG; Jayaram HN
Life Sci; 2000 Nov; 68(1):1-11. PubMed ID: 11132239
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
Bartlett DL; Buell JF; Libutti SK; Reed E; Lee KB; Figg WD; Venzon DJ; Alexander HR
Cancer; 1998 Sep; 83(6):1251-61. PubMed ID: 9740093
[TBL] [Abstract][Full Text] [Related]
7. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells.
Bonavida B; Tsuchitani T; Zighelboim J; Berek JS
Gynecol Oncol; 1990 Sep; 38(3):333-9. PubMed ID: 2227544
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of human malignant glioma cell lines to tumor necrosis factor-induced apoptosis by cisplatin.
Duan L; Aoyagi M; Tamaki M; Nakagawa K; Nagashima G; Nagasaka Y; Ohno K; Yamamoto K; Hirakawa K
J Neurooncol; 2001 Mar; 52(1):23-36. PubMed ID: 11451200
[TBL] [Abstract][Full Text] [Related]
9. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology.
Debes A; Rommel F; Breise M; Willers R; Göbel U; Wessalowski R
Klin Padiatr; 2002; 214(4):223-9. PubMed ID: 12165906
[TBL] [Abstract][Full Text] [Related]
10. Reduction of cellular cisplatin resistance by hyperthermia--a review.
Hettinga JV; Konings AW; Kampinga HH
Int J Hyperthermia; 1997; 13(5):439-57. PubMed ID: 9354931
[TBL] [Abstract][Full Text] [Related]
11. The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs.
Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S
Oncol Rep; 2005 Sep; 14(3):609-15. PubMed ID: 16077963
[TBL] [Abstract][Full Text] [Related]
12. In-vitro effect of a combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) on human gastric cancer cell lines: timing of cisplatin treatment.
Cho H; Imada T; Oshima T; Shiozawa M; Rino Y; Takanashi Y
Gastric Cancer; 2002; 5(1):43-6. PubMed ID: 12021859
[TBL] [Abstract][Full Text] [Related]
13. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
[TBL] [Abstract][Full Text] [Related]
14. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
[TBL] [Abstract][Full Text] [Related]
15. Etoposide enhances the antitumor effects of cisplatin in gastric cancer cells.
Hotta T; Tanimura H; Yamaue H; Iwahashi M; Tani M; Tsunoda T; Noguchi K; Mizobata S; Arii K; Terasawa H
Anticancer Res; 1997; 17(2A):885-9. PubMed ID: 9137422
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of cisplatin sensitivity and platinum uptake by 40 degrees C hyperthermia in resistant cells.
Ohtsubo T; Saito H; Tanaka N; Matsumoto H; Sugimoto C; Saito T; Hayashi S; Kano E
Cancer Lett; 1997 Oct; 119(1):47-52. PubMed ID: 18372521
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
18. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.
Ma GY; Bartlett DL; Reed E; Figg WD; Lush RM; Lee KB; Libutti SK; Alexander HR
Cancer J Sci Am; 1997; 3(3):174-9. PubMed ID: 9161783
[TBL] [Abstract][Full Text] [Related]
19. Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murine model of peritoneal carcinomatosis.
Facy O; Radais F; Ladoire S; Delroeux D; Tixier H; Ghiringhelli F; Rat P; Chauffert B; Ortega-Deballon P
J Exp Clin Cancer Res; 2011 Jan; 30(1):4. PubMed ID: 21214912
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
